peginterferon alfa-2a 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
5158 198153-51-4

Description:

MoleculeDescription

Synonyms:

  • peginterferon alfa-2a
  • pegasys
interferon alfa‑2a attached to polyethylene glycol
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
26 mcg P

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
Oct. 16, 2002 FDA HOFFMAN-LA ROCHE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaemia 2052.29 18.11 1340 29133 351462 90246512
White blood cell count decreased 884.39 18.11 601 29872 166508 90431466
Platelet count decreased 654.48 18.11 463 30010 136506 90461468
Haemoglobin decreased 486.46 18.11 416 30057 161540 90436434
Dysgeusia 330.53 18.11 211 30262 52349 90545625
Anal pruritus 311.83 18.11 71 30402 896 90597078
Leukopenia 308.78 18.11 262 30211 100448 90497526
Exposure via direct contact 293.31 18.11 49 30424 86 90597888
Pancytopenia 287.77 18.11 272 30201 119991 90477983
Thrombocytopenia 261.53 18.11 336 30137 208389 90389585
Anorectal discomfort 235.59 18.11 72 30401 2962 90595012
Rash 234.00 18.11 690 29783 795410 89802564
Haemolytic anaemia 224.43 18.11 99 30374 11598 90586376
Red blood cell count decreased 214.66 18.11 154 30319 46197 90551777
Neutropenia 213.89 18.11 317 30156 224587 90373387
Viral load increased 192.33 18.11 53 30420 1503 90596471
Influenza like illness 192.08 18.11 182 30291 80429 90517545
Neutrophil count decreased 184.89 18.11 169 30304 71363 90526611
Fatigue 169.69 18.11 800 29673 1153223 89444751
Nausea 148.19 18.11 749 29724 1109567 89488407
Depression 141.48 18.11 312 30161 300289 90297685
No adverse event 133.19 18.11 138 30335 67844 90530130
Asthenia 129.78 18.11 434 30039 533317 90064657
Pruritus 126.98 18.11 435 30038 541090 90056884
Ascites 110.27 18.11 106 30367 47634 90550340
Hepatitis C 108.87 18.11 48 30425 5612 90592362
Decreased appetite 100.23 18.11 316 30157 376224 90221750
Arthropathy 93.49 18.11 8 30465 366234 90231740
Pyrexia 90.73 18.11 450 30023 660035 89937939
Drug hypersensitivity 89.16 18.11 23 30450 463586 90134388
Chills 84.69 18.11 156 30317 131825 90466149
Systemic lupus erythematosus 84.45 18.11 11 30462 361885 90236089
Joint swelling 84.24 18.11 32 30441 503268 90094706
Drug reaction with eosinophilia and systemic symptoms 84.09 18.11 87 30386 42671 90555303
Condition aggravated 82.65 18.11 49 30424 595496 90002478
Blood bilirubin increased 79.34 18.11 85 30388 43385 90554589
Product use in unapproved indication 78.98 18.11 10 30463 336226 90261748
Haemorrhoids 78.72 18.11 68 30405 26634 90571340
Peripheral swelling 76.59 18.11 22 30451 413084 90184890
Irritability 76.40 18.11 76 30397 35586 90562388
Drug ineffective 72.12 18.11 233 30240 1384065 89213909
Rash pruritic 69.67 18.11 110 30363 82104 90515870
Retinopathy 68.06 18.11 30 30443 3504 90594470
Drug intolerance 67.65 18.11 33 30440 447558 90150416
Weight decreased 65.51 18.11 277 30196 379633 90218341
Mobility decreased 65.29 18.11 5 30468 250729 90347245
Dry skin 62.76 18.11 109 30364 87964 90510010
Discomfort 62.41 18.11 9 30464 274326 90323648
Hepatic failure 61.02 18.11 71 30402 39657 90558317
Rheumatoid arthritis 60.73 18.11 23 30450 362591 90235383
Helicobacter infection 60.57 18.11 4 30469 226846 90371128
Retinal exudates 60.41 18.11 18 30455 678 90597296
Hepatic enzyme increased 60.21 18.11 23 30450 360713 90237261
Myalgia 60.00 18.11 161 30312 174964 90423010
Lower respiratory tract infection 59.96 18.11 7 30466 250652 90347322
Impaired healing 57.39 18.11 6 30467 234193 90363781
Musculoskeletal stiffness 56.41 18.11 15 30458 296517 90301457
Angiodermatitis 55.83 18.11 13 30460 182 90597792
Psoriatic arthropathy 55.56 18.11 6 30467 228329 90369645
Hepatic cirrhosis 55.49 18.11 86 30387 63167 90534807
Hypothyroidism 54.89 18.11 78 30395 53049 90544925
Injury 54.13 18.11 3 30470 197346 90400628
Toxicity to various agents 53.93 18.11 15 30458 287831 90310143
Osteoarthritis 53.61 18.11 3 30470 195727 90402247
Hyperthyroidism 52.69 18.11 46 30427 18264 90579710
Hypersensitivity 51.82 18.11 46 30427 454631 90143343
Nasopharyngitis 51.65 18.11 37 30436 407067 90190907
Wheezing 51.47 18.11 9 30464 238071 90359903
Insomnia 50.52 18.11 234 30239 333240 90264734
Infection 49.87 18.11 30 30443 362064 90235910
Jaundice 49.75 18.11 58 30415 32459 90565515
Irritable bowel syndrome 49.10 18.11 6 30467 207442 90390532
Abdominal discomfort 48.96 18.11 53 30420 477275 90120699
Hepatitis C RNA increased 48.00 18.11 11 30462 143 90597831
Type 2 diabetes mellitus 47.81 18.11 6 30467 203238 90394736
Pericarditis 47.14 18.11 16 30457 270135 90327839
Face oedema 46.84 18.11 48 30425 23270 90574704
Glossodynia 46.68 18.11 25 30448 321754 90276220
Therapeutic product effect incomplete 44.94 18.11 6 30467 193890 90404084
Hepatocellular carcinoma 44.79 18.11 20 30453 2408 90595566
Vomiting 44.54 18.11 432 30041 787861 89810113
Fibromyalgia 42.04 18.11 9 30464 206260 90391714
Proctalgia 42.01 18.11 29 30444 8169 90589805
C-reactive protein increased 41.13 18.11 6 30467 181383 90416591
Autoimmune thyroiditis 40.37 18.11 25 30448 5868 90592106
Inflammation 40.28 18.11 6 30467 178586 90419388
Haematocrit decreased 38.27 18.11 58 30415 41774 90556200
Poor quality product administered 38.02 18.11 21 30452 3987 90593987
Hepatic encephalopathy 36.45 18.11 33 30440 13739 90584235
Epistaxis 36.19 18.11 85 30388 85040 90512934
Sarcoidosis 35.20 18.11 29 30444 10644 90587330
Hyperuricaemia 34.98 18.11 24 30449 6695 90591279
Completed suicide 34.80 18.11 4 30469 145054 90452920
Product administration error 33.71 18.11 43 30430 26380 90571594
Gastrointestinal disorder 32.96 18.11 23 30450 256664 90341310
Rash papular 32.30 18.11 37 30436 20318 90577656
Urate nephropathy 32.22 18.11 8 30465 149 90597825
Renal failure 32.08 18.11 107 30366 130900 90467074
Basedow's disease 31.95 18.11 9 30464 277 90597697
Lymphadenopathy 31.75 18.11 56 30417 45719 90552255
Transfusion 31.56 18.11 34 30439 17454 90580520
Extradural abscess 31.50 18.11 13 30460 1291 90596683
Dehydration 31.31 18.11 139 30334 194308 90403666
Aquagenic pruritus 31.25 18.11 6 30467 30 90597944
Swelling 30.65 18.11 59 30414 418999 90178975
Alanine aminotransferase increased 30.18 18.11 98 30375 118240 90479734
Fall 30.15 18.11 74 30399 481736 90116238
Pain 30.10 18.11 204 30269 996137 89601837
Thyroid function test abnormal 30.09 18.11 18 30455 3971 90594003
Hepatitis cholestatic 29.78 18.11 24 30449 8537 90589437
Vision blurred 29.64 18.11 93 30380 110200 90487774
Toxic skin eruption 29.05 18.11 31 30442 15743 90582231
Retinal haemorrhage 28.62 18.11 20 30453 5744 90592230
Crying 28.50 18.11 39 30434 25606 90572368
Autoimmune hepatitis 27.78 18.11 25 30448 10326 90587648
Porphyria non-acute 27.01 18.11 8 30465 295 90597679
Gingival bleeding 26.94 18.11 29 30444 14874 90583100
Erythema nodosum 26.43 18.11 19 30454 5705 90592269
Alopecia 26.26 18.11 268 30205 494803 90103171
Facial paralysis 25.94 18.11 29 30444 15505 90582469
Tongue pigmentation 25.88 18.11 5 30468 26 90597948
Mental disorder 25.67 18.11 42 30431 32276 90565698
Full blood count decreased 25.52 18.11 40 30433 29649 90568325
Anger 25.33 18.11 27 30446 13693 90584281
Virologic failure 24.87 18.11 13 30460 2211 90595763
Asthma 24.67 18.11 27 30446 242133 90355841
Vogt-Koyanagi-Harada disease 24.55 18.11 8 30465 406 90597568
Maternal exposure during pregnancy 24.36 18.11 53 30420 360010 90237964
Blood thyroid stimulating hormone increased 24.35 18.11 22 30451 9133 90588841
Hypertension 24.35 18.11 76 30397 457456 90140518
Sciatica 23.81 18.11 3 30470 101379 90496595
Cutaneous sarcoidosis 23.64 18.11 8 30465 457 90597517
Sinusitis 23.63 18.11 50 30423 343038 90254936
Hyperbilirubinaemia 23.25 18.11 26 30447 13910 90584064
Pyelonephritis 23.06 18.11 32 30441 21284 90576690
Cryoglobulinaemia 22.75 18.11 9 30464 801 90597173
Mood swings 22.28 18.11 31 30442 20671 90577303
Hepatic cancer 22.08 18.11 16 30457 4865 90593109
Mouth ulceration 21.64 18.11 44 30429 39930 90558044
Lip dry 21.41 18.11 4 30469 100951 90497023
VIIIth nerve lesion 21.37 18.11 4 30469 17 90597957
Oxygen saturation decreased 21.27 18.11 5 30468 107478 90490496
Treatment failure 21.17 18.11 44 30429 303884 90294090
Weight increased 21.13 18.11 71 30402 417856 90180118
Aspartate aminotransferase increased 20.84 18.11 79 30394 102858 90495116
Guillain-Barre syndrome 20.59 18.11 15 30458 4597 90593377
Febrile neutropenia 20.57 18.11 14 30459 158335 90439639
Suicidal ideation 20.51 18.11 63 30410 73792 90524182
Nervousness 20.26 18.11 39 30434 34017 90563957
Viral load decreased 20.22 18.11 4 30469 24 90597950
Arthralgia 19.86 18.11 167 30306 778355 89819619
Abortion spontaneous 19.81 18.11 51 30422 54005 90543969
Ammonia increased 19.55 18.11 15 30458 4971 90593003
Loss of personal independence in daily activities 19.10 18.11 11 30462 136094 90461880
Bulimia nervosa 19.08 18.11 7 30466 507 90597467
Erythema multiforme 18.99 18.11 22 30451 12224 90585750
Exposure via father 18.66 18.11 6 30467 292 90597682
Adverse drug reaction 18.53 18.11 8 30465 116693 90481281
Demyelinating polyneuropathy 18.15 18.11 8 30465 934 90597040
Osteoporosis 18.12 18.11 5 30468 96526 90501448

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaemia 1223.02 15.38 1303 33060 278975 42307997
White blood cell count decreased 803.00 15.38 683 33680 109713 42477259
Rash 677.35 15.38 964 33399 275990 42310982
Platelet count decreased 458.94 15.38 561 33802 138020 42448952
Influenza like illness 389.51 15.38 269 34094 31571 42555401
Fatigue 383.71 15.38 981 33382 434660 42152312
Anorectal discomfort 343.29 15.38 110 34253 2145 42584827
Pruritus 334.77 15.38 568 33795 188203 42398769
Depression 296.36 15.38 405 33958 110958 42476014
Haemoglobin decreased 275.83 15.38 429 33934 132042 42454930
Dysgeusia 260.91 15.38 218 34145 33971 42553001
Anal pruritus 235.29 15.38 57 34306 365 42586607
Thrombocytopenia 227.11 15.38 484 33879 189795 42397177
Insomnia 220.05 15.38 364 33999 117889 42469083
Leukopenia 211.07 15.38 280 34083 74466 42512506
Irritability 179.49 15.38 162 34201 27966 42559006
Viral load increased 158.08 15.38 67 34296 2930 42584042
Hepatic cirrhosis 157.26 15.38 129 34234 19573 42567399
Hepatitis C 153.77 15.38 98 34265 10035 42576937
Red blood cell count decreased 149.68 15.38 157 34206 32558 42554414
Nausea 133.04 15.38 651 33712 396148 42190824
Exposure via direct contact 132.45 15.38 24 34339 20 42586952
Neutropenia 131.73 15.38 406 33957 199025 42387947
Neutrophil count decreased 124.25 15.38 200 34163 63215 42523757
Haemorrhoids 122.10 15.38 105 34258 16992 42569980
Pancytopenia 113.98 15.38 276 34087 117467 42469505
Retinal exudates 111.85 15.38 37 34326 800 42586172
Toxicity to various agents 104.27 15.38 28 34335 229108 42357864
Product use in unapproved indication 101.90 15.38 14 34349 184442 42402530
Headache 98.78 15.38 418 33945 238951 42348021
Febrile neutropenia 91.75 15.38 19 34344 185684 42401288
Rash pruritic 88.81 15.38 122 34241 33481 42553491
Retinopathy 78.94 15.38 38 34325 2243 42584729
Dry skin 76.88 15.38 139 34224 48199 42538773
Decreased appetite 75.53 15.38 332 34031 192805 42394167
Hepatocellular carcinoma 74.65 15.38 58 34305 8136 42578836
Off label use 71.37 15.38 270 34093 638065 41948907
Malignant neoplasm progression 71.16 15.38 4 34359 108396 42478576
Abortion spontaneous 71.01 15.38 22 34341 382 42586590
Condition aggravated 66.92 15.38 67 34296 260687 42326285
Hypotension 65.19 15.38 67 34296 257564 42329408
Ascites 63.70 15.38 141 34222 56537 42530435
Proctalgia 62.00 15.38 49 34314 7044 42579928
Blood bilirubin increased 61.53 15.38 117 34246 42135 42544837
Weight decreased 60.15 15.38 328 34035 207620 42379352
No adverse event 59.24 15.38 110 34253 38911 42548061
Depressed mood 58.93 15.38 83 34280 23301 42563671
Acute kidney injury 57.89 15.38 132 34231 367205 42219767
Drug abuse 57.70 15.38 8 34355 104763 42482209
Death 54.68 15.38 196 34167 470989 42115983
Hepatic cancer 52.41 15.38 48 34315 8432 42578540
Fall 51.75 15.38 68 34295 234452 42352520
Pyrexia 51.57 15.38 514 33849 393528 42193444
Product use issue 49.85 15.38 3 34360 76748 42510224
Bradycardia 48.33 15.38 6 34357 85478 42501494
Facial paralysis 44.87 15.38 53 34310 12510 42574462
Mood swings 43.30 15.38 44 34319 8782 42578190
Alopecia 42.53 15.38 81 34282 29195 42557777
Hepatic encephalopathy 42.38 15.38 59 34304 16383 42570589
Myalgia 42.00 15.38 171 34192 95909 42491063
Asthenia 41.99 15.38 377 33986 280416 42306556
Pregnancy of partner 41.69 15.38 15 34348 420 42586552
Chills 41.58 15.38 168 34195 93898 42493074
Disease progression 41.49 15.38 33 34330 143623 42443349
Hyponatraemia 41.42 15.38 15 34348 101447 42485525
Hepatic failure 40.80 15.38 93 34270 38007 42548965
Retinal haemorrhage 40.30 15.38 35 34328 5735 42581237
Sarcoidosis 40.08 15.38 29 34334 3653 42583319
Therapeutic product effect incomplete 40.05 15.38 5 34358 70934 42516038
Therapy non-responder 38.26 15.38 112 34251 53247 42533725
Haemolytic anaemia 38.17 15.38 48 34315 12079 42574893
Completed suicide 38.15 15.38 15 34348 96450 42490522
Varices oesophageal 37.82 15.38 30 34333 4335 42582637
Infusion related reaction 37.67 15.38 3 34360 60803 42526169
C-reactive protein increased 37.08 15.38 4 34359 63556 42523416
Pregnancy 36.42 15.38 12 34351 256 42586716
Acute stress disorder 36.40 15.38 11 34352 175 42586797
Intentional product misuse 35.84 15.38 4 34359 61896 42525076
Respiratory failure 35.07 15.38 31 34332 128101 42458871
Toxic skin eruption 34.98 15.38 49 34314 13681 42573291
Injection site rash 34.65 15.38 32 34331 5680 42581292
Hyperkalaemia 34.39 15.38 11 34352 80447 42506525
Peripheral swelling 34.14 15.38 15 34348 90255 42496717
Drug hypersensitivity 33.84 15.38 19 34344 99370 42487602
Tachycardia 33.46 15.38 20 34343 101067 42485905
Cardiac failure congestive 32.73 15.38 14 34349 85588 42501384
Blood pressure increased 32.58 15.38 21 34342 101907 42485065
Atrial fibrillation 32.29 15.38 39 34324 139554 42447418
Dry mouth 31.80 15.38 87 34276 39792 42547180
Vision blurred 31.37 15.38 105 34258 53594 42533378
Cryoglobulinaemia 31.14 15.38 13 34350 547 42586425
Hepatitis C RNA increased 31.02 15.38 11 34352 295 42586677
Facial paresis 29.59 15.38 23 34340 3227 42583745
Porphyria non-acute 29.27 15.38 12 34351 482 42586490
Mucosal inflammation 29.07 15.38 3 34360 49371 42537601
Product administration error 28.19 15.38 52 34311 18291 42568681
Therapy responder 27.81 15.38 9 34354 181 42586791
Oesophageal varices haemorrhage 27.48 15.38 23 34340 3584 42583388
Autoimmune hepatitis 27.43 15.38 28 34335 5617 42581355
Hypoxia 27.34 15.38 11 34352 69775 42517197
Drug reaction with eosinophilia and systemic symptoms 26.13 15.38 84 34279 41991 42544981
Hospitalisation 25.60 15.38 14 34349 74316 42512656
Normal newborn 25.45 15.38 10 34353 359 42586613
Virologic failure 25.45 15.38 23 34340 3971 42583001
Injection site erythema 24.68 15.38 52 34311 20143 42566829
Product quality issue 24.17 15.38 48 34315 17834 42569138
General physical health deterioration 24.02 15.38 54 34309 151192 42435780
Treatment failure 23.90 15.38 107 34256 62517 42524455
Deafness unilateral 23.77 15.38 17 34346 2102 42584870
Suicidal ideation 23.69 15.38 89 34274 48072 42538900
Chronic obstructive pulmonary disease 23.06 15.38 11 34352 63103 42523869
Wrong dose 22.97 15.38 13 34350 1071 42585901
Alanine aminotransferase increased 22.56 15.38 135 34228 88271 42498701
Hypoglycaemia 22.54 15.38 10 34353 59844 42527128
Portal hypertension 21.92 15.38 23 34340 4764 42582208
Somnolence 21.90 15.38 51 34312 141054 42445918
Gastrointestinal haemorrhage 21.86 15.38 28 34335 97698 42489274
Hypertension 21.74 15.38 66 34297 167138 42419834
Therapeutic product effect decreased 21.52 15.38 3 34360 39147 42547825
Mood altered 21.22 15.38 34 34329 10684 42576288
Wheezing 20.87 15.38 9 34354 54772 42532200
Viral load 20.77 15.38 6 34357 81 42586891
Disturbance in attention 20.74 15.38 62 34301 29804 42557168
Borderline personality disorder 20.48 15.38 9 34354 430 42586542
Drug ineffective for unapproved indication 20.28 15.38 6 34357 46157 42540815
Serum ferritin increased 20.26 15.38 27 34336 7192 42579780
Anger 20.12 15.38 37 34326 12981 42573991
Anaphylactic reaction 19.82 15.38 5 34358 42738 42544234
Peritonitis bacterial 19.62 15.38 26 34337 6889 42580083
Basedow's disease 19.56 15.38 5 34358 41 42586931
Ear injury 19.56 15.38 5 34358 41 42586931
Pneumonia aspiration 19.44 15.38 8 34355 50070 42536902
Oral lichen planus 19.36 15.38 7 34356 199 42586773
Oral herpes 19.33 15.38 27 34336 7517 42579455
Prostate cancer 19.26 15.38 6 34357 44637 42542335
Drug ineffective 19.15 15.38 376 33987 629821 41957151
Premature rupture of membranes 18.96 15.38 4 34359 12 42586960
Skin disorder 18.84 15.38 42 34321 16902 42570070
Jaundice 18.77 15.38 66 34297 34523 42552449
Memory impairment 18.55 15.38 85 34278 50137 42536835
Blood iron increased 18.39 15.38 11 34352 1005 42585967
Pulmonary oedema 18.39 15.38 10 34353 53262 42533710
Asthma 18.37 15.38 14 34349 62300 42524672
Photosensitivity reaction 18.26 15.38 35 34328 12667 42574305
Cardiac arrest 18.21 15.38 38 34325 109282 42477690
Tinnitus 18.17 15.38 58 34305 28880 42558092
Smooth muscle antibody positive 17.88 15.38 4 34359 17 42586955
Psychotic disorder 17.85 15.38 58 34305 29150 42557822
Homicidal ideation 17.62 15.38 16 34347 2778 42584194
Metabolic acidosis 17.52 15.38 10 34353 51848 42535124
Product dose omission issue 17.29 15.38 65 34298 154300 42432672
Mental disorder 17.11 15.38 42 34321 17987 42568985
Haematuria 17.02 15.38 13 34350 57786 42529186
Musculoskeletal stiffness 17 15.38 13 34350 57752 42529220
Lower respiratory tract infection 16.96 15.38 6 34357 41200 42545772
Hepatitis C RNA positive 16.71 15.38 6 34357 167 42586805
Abortion induced 16.54 15.38 6 34357 172 42586800
Hepatitis C virus test positive 16.36 15.38 7 34356 313 42586659
Rash papular 16.32 15.38 32 34331 11779 42575193
Liver transplant 16.18 15.38 15 34348 2676 42584296
Affect lability 16.02 15.38 18 34345 4026 42582946
Coronary artery disease 15.92 15.38 12 34351 53708 42533264
Intentional overdose 15.90 15.38 11 34352 51445 42535527
Pain in extremity 15.85 15.38 65 34298 150539 42436433
Cardiac disorder 15.74 15.38 10 34353 48922 42538050
Gingival bleeding 15.56 15.38 26 34337 8459 42578513
Acute respiratory failure 15.42 15.38 6 34357 38852 42548120

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaemia 2337.00 14.60 1853 42862 545233 109999351
White blood cell count decreased 1380.07 14.60 958 43757 228432 110316152
Platelet count decreased 914.32 14.60 751 43964 229692 110314892
Haemoglobin decreased 571.44 14.60 598 44117 248129 110296455
Leukopenia 521.41 14.60 452 44263 148339 110396245
Thrombocytopenia 485.48 14.60 649 44066 348236 110196348
Rash 472.63 14.60 1029 43686 819935 109724649
Influenza like illness 387.58 14.60 306 44409 88106 110456478
Dysgeusia 363.46 14.60 268 44447 69717 110474867
Pancytopenia 359.33 14.60 433 44282 209180 110335404
Neutropenia 322.94 14.60 558 44157 374062 110170522
Anal pruritus 312.36 14.60 75 44640 992 110543592
Neutrophil count decreased 308.47 14.60 308 44407 120633 110423951
Fatigue 302.45 14.60 1125 43590 1214833 109329751
Anorectal discomfort 274.67 14.60 91 44624 4035 110540549
Pruritus 264.60 14.60 666 44049 580894 109963690
Depression 262.02 14.60 464 44251 316871 110227713
Hepatitis C 230.32 14.60 109 44606 12464 110532120
Red blood cell count decreased 214.07 14.60 192 44523 65731 110478853
Irritability 206.23 14.60 164 44551 47645 110496939
Viral load increased 195.01 14.60 67 44648 3323 110541261
Haemolytic anaemia 188.50 14.60 113 44602 20807 110523777
Insomnia 171.02 14.60 420 44295 360170 110184414
Blood bilirubin increased 155.24 14.60 172 44543 75800 110468784
Infusion related reaction 139.56 14.60 3 44712 381159 110163425
Retinal exudates 134.31 14.60 40 44675 1244 110543340
Ascites 133.74 14.60 176 44539 92632 110451952
Hepatocellular carcinoma 131.63 14.60 69 44646 9811 110534773
Decreased appetite 128.94 14.60 454 44261 475392 110069192
Nausea 128.15 14.60 895 43820 1234795 109309789
Retinopathy 124.99 14.60 52 44663 4377 110540207
Hepatic cirrhosis 119.41 14.60 142 44573 67484 110477100
Pyrexia 118.51 14.60 692 44023 897573 109647011
Product use in unapproved indication 117.14 14.60 20 44695 447357 110097227
Toxicity to various agents 116.33 14.60 26 44689 480529 110064055
Haemorrhoids 115.97 14.60 104 44611 35568 110509016
Dry skin 115.01 14.60 177 44538 107476 110437108
Drug hypersensitivity 109.04 14.60 25 44690 454065 110090519
Product use issue 105.06 14.60 5 44710 311690 110232894
Condition aggravated 102.53 14.60 88 44627 734748 109809836
Asthenia 102.15 14.60 548 44167 688451 109856133
Hepatic failure 101.57 14.60 132 44583 68607 110475977
Arthropathy 95.66 14.60 5 44710 287517 110257067
Peripheral swelling 93.55 14.60 24 44691 404010 110140574
Joint swelling 90.49 14.60 33 44682 442812 110101772
Weight decreased 88.35 14.60 399 44316 467658 110076926
Lower respiratory tract infection 81.59 14.60 4 44711 243102 110301482
Rash pruritic 80.20 14.60 143 44572 97926 110446658
Myalgia 79.96 14.60 234 44481 222147 110322437
Wound 78.22 14.60 4 44711 234433 110310151
Drug reaction with eosinophilia and systemic symptoms 78.05 14.60 128 44587 81967 110462617
Therapeutic product effect decreased 76.08 14.60 6 44709 244310 110300274
Chills 75.79 14.60 208 44507 190372 110354212
Mobility decreased 73.45 14.60 6 44709 237416 110307168
Drug intolerance 70.89 14.60 38 44677 406474 110138110
Hepatic encephalopathy 70.17 14.60 71 44644 28185 110516399
Musculoskeletal stiffness 70.00 14.60 14 44701 279808 110264776
Wheezing 67.67 14.60 11 44704 255219 110289365
Febrile neutropenia 67.45 14.60 22 44693 316745 110227839
Alanine aminotransferase increased 66.64 14.60 194 44521 183579 110361005
Systemic lupus erythematosus 65.15 14.60 12 44703 254326 110290258
Fall 63.51 14.60 91 44624 603391 109941193
Hypersensitivity 63.12 14.60 43 44672 403955 110140629
C-reactive protein increased 60.99 14.60 8 44707 217911 110326673
Injury 59.21 14.60 3 44712 177262 110367322
Drug ineffective 59.15 14.60 367 44348 1520173 109024411
Toxic skin eruption 59.14 14.60 64 44651 27451 110517133
Therapeutic product effect incomplete 58.54 14.60 10 44705 223795 110320789
Jaundice 58.53 14.60 94 44621 59142 110485442
Malignant neoplasm progression 58.16 14.60 3 44712 174564 110370020
Psoriatic arthropathy 58.11 14.60 6 44709 196755 110347829
Helicobacter infection 57.95 14.60 4 44711 181873 110362711
Retinal haemorrhage 57.58 14.60 40 44675 9461 110535123
Completed suicide 56.84 14.60 14 44701 242367 110302217
Blood cholesterol increased 56.25 14.60 5 44710 184780 110359804
Virologic failure 55.94 14.60 31 44684 4921 110539663
Hyperbilirubinaemia 55.11 14.60 65 44650 30606 110513978
Proctalgia 54.11 14.60 44 44671 13178 110531406
Angiodermatitis 53.06 14.60 13 44702 188 110544396
Osteoarthritis 52.83 14.60 6 44709 182617 110361967
Exposure via direct contact 52.62 14.60 11 44704 73 110544511
Hyperuricaemia 52.51 14.60 45 44670 14486 110530098
Oxygen saturation decreased 51.36 14.60 3 44712 156979 110387605
Fibromyalgia 51.02 14.60 5 44710 170904 110373680
Drug abuse 50.89 14.60 6 44709 177405 110367179
Mood swings 48.92 14.60 53 44662 22759 110521825
Hypotension 48.47 14.60 86 44629 523763 110020821
Rheumatoid arthritis 47.98 14.60 31 44684 299582 110245002
Depressed mood 47.57 14.60 87 44628 60722 110483862
Folliculitis 47.28 14.60 6 44709 167647 110376937
Basedow's disease 47.22 14.60 12 44703 203 110544381
Facial paralysis 46.32 14.60 53 44662 24161 110520423
Off label use 46.20 14.60 387 44328 1499798 109044786
Nasopharyngitis 46.03 14.60 55 44660 394306 110150278
Irritable bowel syndrome 46.02 14.60 6 44709 164209 110380375
Autoimmune hepatitis 45.83 14.60 42 44673 14762 110529822
Vision blurred 45.60 14.60 135 44580 128887 110415697
Sarcoidosis 45.54 14.60 39 44676 12540 110532044
Varices oesophageal 45.19 14.60 31 44684 7184 110537400
COVID-19 44.04 14.60 22 44693 245038 110299546
Inflammation 43.70 14.60 12 44703 193226 110351358
Hepatic enzyme increased 42.77 14.60 40 44675 320852 110223732
Hyperthyroidism 41.37 14.60 55 44660 29206 110515378
Hepatic cancer 41.23 14.60 35 44680 11121 110533463
Bursitis 40.97 14.60 3 44712 129915 110414669
Headache 40.96 14.60 540 44175 881837 109662747
Cutaneous sarcoidosis 39.72 14.60 13 44702 554 110544030
Death 39.06 14.60 148 44567 698721 109845863
Glossodynia 38.31 14.60 21 44694 221983 110322601
No adverse event 38.11 14.60 89 44626 73750 110470834
Aspartate aminotransferase increased 37.64 14.60 146 44569 159790 110384794
Discomfort 37.50 14.60 20 44695 214687 110329897
Deafness unilateral 37.09 14.60 23 44692 4496 110540088
Intentional product misuse 36.89 14.60 5 44710 132899 110411685
Autoimmune thyroiditis 36.46 14.60 26 44689 6408 110538176
Porphyria non-acute 36.04 14.60 13 44702 744 110543840
Gingival bleeding 35.57 14.60 42 44673 19797 110524787
Joint range of motion decreased 35.24 14.60 4 44711 121828 110422756
Type 2 diabetes mellitus 34.84 14.60 14 44701 177218 110367366
Asthma 34.78 14.60 30 44685 250261 110294323
Obesity 34.67 14.60 3 44712 113348 110431236
Blood pressure increased 34.67 14.60 32 44683 258341 110286243
Face oedema 34.28 14.60 54 44661 33415 110511169
Epistaxis 33.99 14.60 123 44592 130249 110414335
Psychotic disorder 33.84 14.60 68 44647 50869 110493715
Tinnitus 33.48 14.60 75 44640 60465 110484119
Injection site rash 33.07 14.60 44 44671 23375 110521209
Infection 32.11 14.60 61 44654 362139 110182445
Anger 32.04 14.60 39 44676 18968 110525616
Suicidal ideation 31.97 14.60 97 44618 93840 110450744
Acute stress disorder 31.81 14.60 11 44704 556 110544028
Liver injury 31.04 14.60 11 44704 150402 110394182
Disease progression 30.69 14.60 32 44683 244002 110300582
Skin disorder 30.58 14.60 59 44656 42854 110501730
Hepatitis C RNA increased 30.49 14.60 10 44705 429 110544155
Cryoglobulinaemia 29.44 14.60 13 44702 1266 110543318
Smooth muscle antibody positive 29.41 14.60 8 44707 178 110544406
Erythema nodosum 29.05 14.60 23 44692 6630 110537954
Peritonitis bacterial 29.00 14.60 28 44687 10505 110534079
Abdominal discomfort 28.62 14.60 74 44641 393784 110150800
Hypothyroidism 28.39 14.60 79 44636 72820 110471764
Pericarditis 28.38 14.60 28 44687 219086 110325498
Maternal exposure during pregnancy 28.21 14.60 37 44678 254846 110289738
Weight increased 28.13 14.60 82 44633 419562 110125022
Disturbance in attention 28.01 14.60 71 44644 61924 110482660
Urate nephropathy 27.87 14.60 8 44707 218 110544366
Skin lesion 27.48 14.60 63 44652 51568 110493016
Erythema multiforme 27.31 14.60 38 44677 21059 110523525
Hepatitis C RNA positive 27.01 14.60 8 44707 244 110544340
Hospitalisation 26.81 14.60 12 44703 142481 110402103
Intentional product use issue 26.41 14.60 37 44678 247869 110296715
Swelling 26.24 14.60 65 44650 350976 110193608
Impaired healing 25.64 14.60 25 44690 196692 110347892
Pain 25.52 14.60 255 44460 954700 109589884
Injection site dermatitis 24.96 14.60 5 44710 26 110544558
Gastrointestinal disorder 24.90 14.60 37 44678 241915 110302669
Type 1 diabetes mellitus 24.81 14.60 24 44691 9023 110535561
Rash papular 24.79 14.60 42 44673 27597 110516987
Liver transplant 24.76 14.60 18 44697 4571 110540013
Hypertension 24.75 14.60 114 44601 509970 110034614
Exposure during pregnancy 24.58 14.60 19 44696 167405 110377179
Photosensitivity reaction 24.45 14.60 40 44675 25549 110519035
Hypoxia 24.22 14.60 11 44704 129504 110415080
Bilirubin conjugated increased 23.98 14.60 20 44695 6204 110538380
Extradural abscess 23.71 14.60 13 44702 2021 110542563
Bradycardia 23.67 14.60 17 44698 155500 110389084
Oesophageal varices haemorrhage 23.56 14.60 18 44697 4927 110539657
Pain in extremity 23.56 14.60 109 44606 487009 110057575
Vogt-Koyanagi-Harada disease 23.54 14.60 9 44706 607 110543977
Hepatitis cholestatic 23.28 14.60 32 44683 17534 110527050
Haematocrit decreased 23.18 14.60 69 44646 66048 110478536
Bone marrow failure 22.83 14.60 63 44652 57785 110486799
Atrial fibrillation 22.78 14.60 36 44679 229606 110314978
Therapy responder 22.42 14.60 8 44707 444 110544140
Tongue pigmentation 22.38 14.60 5 44710 47 110544537
Skin irritation 22.04 14.60 30 44685 16289 110528295
Dermatitis 21.99 14.60 40 44675 27797 110516787
Lip dry 21.20 14.60 7 44708 100076 110444508
Nephrotic syndrome 21.11 14.60 27 44688 13804 110530780
Haemochromatosis 21.10 14.60 11 44704 1546 110543038
Cardiac failure congestive 21.09 14.60 18 44697 150982 110393602
Bulimia nervosa 21.07 14.60 7 44708 313 110544271
Anaphylactic reaction 20.92 14.60 10 44705 114290 110430294
Hepatitis C virus test 20.90 14.60 5 44710 65 110544519
Urticaria 20.86 14.60 63 44652 318794 110225790
Intentional overdose 20.80 14.60 14 44701 132487 110412097
Retinal detachment 20.73 14.60 24 44691 11076 110533508
Aplastic anaemia 20.57 14.60 36 44679 24272 110520312
Wrong dose 20.52 14.60 13 44702 2636 110541948
Upper respiratory tract infection 20.45 14.60 14 44701 131314 110413270
Portal hypertension 20.17 14.60 21 44694 8616 110535968
VIIIth nerve lesion 20.10 14.60 4 44711 20 110544564
Hepatic pain 20.02 14.60 16 44699 4674 110539910
Sudden hearing loss 19.77 14.60 12 44703 2257 110542327
Loss of personal independence in daily activities 19.62 14.60 19 44696 150001 110394583
Stress 19.62 14.60 9 44706 105339 110439245
Hepatic fibrosis 19.54 14.60 20 44695 8046 110536538
Serum ferritin increased 19.47 14.60 24 44691 11823 110532761
Flushing 19.42 14.60 9 44706 104727 110439857
Transfusion 19.36 14.60 36 44679 25436 110519148
Prurigo 19.28 14.60 10 44705 1390 110543194
Hyperkalaemia 19.20 14.60 16 44699 135780 110408804
Homicidal ideation 19.06 14.60 14 44701 3613 110540971
Lymphadenopathy 19.04 14.60 63 44652 63772 110480812
Hyponatraemia 18.97 14.60 37 44678 217616 110326968
Renal failure 18.70 14.60 156 44559 226418 110318166
Sciatica 18.65 14.60 7 44708 92392 110452192
Mood altered 18.54 14.60 32 44683 21343 110523241
Acute kidney injury 18.51 14.60 166 44549 635264 109909320
Transaminases increased 18.41 14.60 62 44653 63328 110481256
Lower limb fracture 18.35 14.60 4 44711 75344 110469240
Wound infection 18.34 14.60 8 44707 96457 110448127
Hepatorenal syndrome 18.18 14.60 15 44700 4582 110540002
Adverse drug reaction 18.18 14.60 10 44705 105549 110439035
Granulocytopenia 18.12 14.60 24 44691 12691 110531893
Portal vein thrombosis 18.01 14.60 18 44697 7040 110537544
Chronic obstructive pulmonary disease 17.87 14.60 11 44704 109147 110435437
Joint stiffness 17.58 14.60 3 44712 67240 110477344
Injection site pain 17.54 14.60 28 44687 177894 110366690
Hepatitis C RNA fluctuation 17.50 14.60 3 44712 5 110544579
Drug ineffective for unapproved indication 17.34 14.60 10 44705 102828 110441756
Pregnancy of partner 17.30 14.60 6 44709 306 110544278
Haemorrhoids thrombosed 17.11 14.60 6 44709 316 110544268
Mental disorder 17.08 14.60 44 44671 38747 110505837
Osteoporosis 16.93 14.60 7 44708 87145 110457439
Retinal disorder 16.81 14.60 11 44704 2359 110542225
Product dose omission issue 16.76 14.60 70 44645 321712 110222872
Mucosal inflammation 16.72 14.60 9 44706 96132 110448452
Aplasia pure red cell 16.71 14.60 20 44695 9558 110535026
Hypercholesterolaemia 16.55 14.60 8 44707 90829 110453755
Meningitis 16.54 14.60 22 44693 11680 110532904
Sinusitis 16.42 14.60 63 44652 296625 110247959
Acute respiratory failure 16.41 14.60 5 44710 75255 110469329
Rash erythematous 16.31 14.60 71 44644 81761 110462823
Lung disorder 16.22 14.60 30 44685 180017 110364567
Thrombotic thrombocytopenic purpura 16.09 14.60 17 44698 7094 110537490
Contusion 16.07 14.60 45 44670 233316 110311268
Musculoskeletal pain 16.05 14.60 31 44684 182992 110361592
Drug eruption 16.04 14.60 53 44662 53606 110490978
Plasma cell myeloma 16.04 14.60 3 44712 62933 110481651
Haemorrhoidal haemorrhage 15.96 14.60 18 44697 8075 110536509
Arthritis 15.94 14.60 27 44688 167559 110377025
Pyelonephritis 15.93 14.60 33 44682 25217 110519367
Granulocyte count decreased 15.79 14.60 13 44702 3961 110540623
Amyotrophy 15.76 14.60 7 44708 691 110543893
General physical health deterioration 15.71 14.60 104 44611 425191 110119393
Muscular weakness 15.60 14.60 50 44665 248418 110296166
Alopecia 15.52 14.60 220 44495 364533 110180051
Borderline personality disorder 15.48 14.60 8 44707 1104 110543480
Thyroid function test abnormal 15.48 14.60 12 44703 3355 110541229
Anti-erythropoietin antibody positive 15.47 14.60 7 44708 722 110543862
Tachycardia 15.38 14.60 44 44671 226601 110317983
Colitis ulcerative 15.38 14.60 6 44709 77357 110467227
Somnolence 15.31 14.60 65 44650 297384 110247200
Optic nerve cupping 15.25 14.60 4 44711 77 110544507
Sjogren's syndrome 15.23 14.60 7 44708 748 110543836
Orthostatic hypotension 15.19 14.60 4 44711 66245 110478339
Frequent bowel movements 15.11 14.60 5 44710 71385 110473199
Metabolic acidosis 15.05 14.60 11 44704 99733 110444851
Orchitis noninfective 14.91 14.60 3 44712 16 110544568
Demyelinating polyneuropathy 14.89 14.60 10 44705 2239 110542345
Guillain-Barre syndrome 14.89 14.60 20 44695 10724 110533860
Vertigo 14.82 14.60 72 44643 86798 110457786
White blood cell count 14.81 14.60 5 44710 235 110544349
Eczema 14.62 14.60 63 44652 72230 110472354
Nasal congestion 14.62 14.60 11 44704 98271 110446313

FDA Adverse Event Reporting System (Pediatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Chordee 25.91 12.82 3 6 0 113944

Pharmacologic Action:

SourceCodeDescription
ATC L03AB11 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
IMMUNOSTIMULANTS
IMMUNOSTIMULANTS
Interferons
ATC L03AB61 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
IMMUNOSTIMULANTS
IMMUNOSTIMULANTS
Interferons
FDA CS M0025711 Interferon-alpha
FDA EPC N0000175521 Interferon alpha
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000998 Antiviral Agents
CHEBI has role CHEBI:22587 antiviral agent
CHEBI has role CHEBI:33282 antibacterial agent
CHEBI has role CHEBI:35441 antiinfective agent
CHEBI has role CHEBI:35469 antidepressant
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:62868 hepatoprotective agent
CHEBI has role CHEBI:64946 anti-HIV agent
CHEBI has role CHEBI:64951 anti-HBV agent
CHEBI has role CHEBI:231911 renoprotective agent
CHEBI has role CHEBI:233423 antifibrotic agent

Related Drugs by ATC class:

L03AB Interferons 6 drugs
interferon alfa-2binterferon beta-1ainterferon beta-1bpeginterferon alfa-2bpeginterferon beta-1aropeginterferon alfa-2b

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Chronic type B viral hepatitis indication 61977001
Chronic hepatitis C indication 128302006




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Interferon alpha/beta receptor Membrane receptor AGONIST DRUG LABEL DRUG LABEL

External reference:

IDSource
Q46947FE7K UNII
4021362 VANDF
C0391001 UMLSCUI
CHEBI:749533 CHEBI
CHEMBL1201560 ChEMBL_ID
DB00008 DRUGBANK_ID
7871 INN_ID
C100416 MESH_SUPPLEMENTAL_RECORD_UI
120608 RXNORM
398841009 SNOMEDCT_US
421559001 SNOMEDCT_US
17012 MMSL
45142 MMSL
d04821 MMSL
009711 NDDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Pegasys HUMAN PRESCRIPTION DRUG LABEL 1 82154-0449 INJECTION, SOLUTION 180 ug SUBCUTANEOUS BLA 32 sections
Pegasys HUMAN PRESCRIPTION DRUG LABEL 1 82154-0451 INJECTION, SOLUTION 180 ug SUBCUTANEOUS BLA 32 sections